Welcome to our dedicated page for BioNTech SE SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioNTech SE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioNTech SE's regulatory disclosures and financial reporting.
BioNTech SE director Anja Morawietz has filed an initial ownership report showing a modest equity stake in the company. The filing lists beneficial ownership of 200 ordinary shares held directly and an additional 40 ordinary shares held indirectly by her immediate family, as described in the footnote. This Form 3 does not report any recent share purchases or sales; it simply establishes her current holdings as she becomes a reporting insider.
BioNTech SE director Rudolf Staudigl filed an initial ownership report showing he holds 400 Ordinary Shares of the company. These shares are reported as held directly, and the filing does not list any recent purchase, sale, or other transaction activity, only the existing position.
BioNTech SE Chief Executive Officer Ugur Sahin filed an initial ownership report detailing his direct, indirect and derivative interests in the company’s ordinary shares. The filing shows indirect ownership of 40,132,788 ordinary shares held through Medine GmbH, which he wholly owns and may be deemed to beneficially own. It also lists 858,209 ordinary shares held directly.
In addition, Sahin holds several option and phantom option awards and performance share units tied to BioNTech ordinary shares, with various exercise prices and expiration dates extending to 2035. These awards generally vest in equal annual installments over four years and are subject to performance-based and other conditions.
BioNTech SE filed an initial beneficial ownership report for Chief Financial Officer Ramon Zapata Gomez on Form 3. This filing formally registers him as an officer subject to insider reporting rules. The available data shows no transactions or derivative positions reported in this Form 3 excerpt.
BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.
BioNTech SE filed an initial insider ownership report for Chief People Officer Kylie Jimenez. This Form 3 establishes her status as a reporting person under U.S. securities rules. The filing does not list any transactions or option exercises; it simply opens ongoing disclosure of future activity.
BioNTech SE is highlighting progress in its late-stage lung cancer portfolio with new clinical data to be presented at the European Lung Cancer Congress 2026 in Copenhagen. The company will showcase programs spanning immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies across multiple lung cancer settings.
Key updates include pumitamig, a PD-L1×VEGF-A bispecific immunomodulator with encouraging antitumor activity and survival outcomes in several Phase 1/2 trials in China, supporting ongoing global ROSETTA Lung-01 and Lung-02 trials. Gotistobart, a CTLA-4–targeting candidate, showed clinically meaningful antitumor activity and a 54% reduction in risk of death versus standard chemotherapy in stage 1 of the global Phase 3 PRESERVE-003 study in squamous NSCLC.
BioNTech also reported first clinical data for BNT326/YL202, a HER3-targeted ADC, in advanced NSCLC with antitumor activity and favorable safety, backing a combination trial with pumitamig. Overall, BioNTech is running 16 lung cancer trials, including four pivotal Phase 3 and five novel-novel combination studies.
BioNTech SE director Michael Motschmann has filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and, in the data provided, does not report any insider buy, sell, gift, or option exercise transactions.
BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares. He holds options and phantom options over 18,416, 25,459, 8,838, 7,112 and 14,664 underlying ordinary shares with exercise prices including 113.9400, 185.2300 and 152.1000, expiring between 2031 and 2035. He also reports 11,047 performance share units tied to ordinary shares. In addition, he has 141,514 ordinary shares directly, 449,387 ordinary shares held through Tofino GmbH, where he is sole shareholder, and 1,638 ordinary shares held by immediate family, for which he disclaims beneficial ownership except for any pecuniary interest.
BioNTech SE director Helmut Wolfgang Jeggle reported his initial ownership of the company’s ordinary shares. The Form 3 shows he holds 332,316 ordinary shares directly and 656,951 ordinary shares indirectly as of March 18, 2026. The indirect shares are held by Salvia GmbH, where he serves as Chief Executive Officer and may be deemed to beneficially own the shares held by that entity.